{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:24:40Z","timestamp":1757701480191},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T00:00:00Z","timestamp":1520640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00417-018-3952-6","type":"journal-article","created":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T17:39:36Z","timestamp":1520703576000},"page":"1355-1356","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reply to the letter to the editor: Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success"],"prefix":"10.1007","volume":"256","author":[{"given":"Rita","family":"Laiginhas","sequence":"first","affiliation":[]},{"given":"Marta In\u00eas","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Manuel Sousa","family":"Falc\u00e3o","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,3,10]]},"reference":[{"key":"3952_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00417-017-3836-1","volume":"256","author":"R Laiginhas","year":"2018","unstructured":"Laiginhas R, Silva MI, Rosas V et al (2018) Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Graefes Arch Clin Exp Ophthalmol 256:83\u201389. \n                    https:\/\/doi.org\/10.1007\/s00417-017-3836-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3952_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40265-017-0704-6","volume":"77","author":"SU Shah","year":"2017","unstructured":"Shah SU, Maturi RK (2017) Therapeutic options in refractory diabetic macular oedema. Drugs 77:481\u2013492. \n                    https:\/\/doi.org\/10.1007\/s40265-017-0704-6","journal-title":"Drugs"},{"key":"3952_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00417-017-3828-1","volume":"256","author":"SG Karst","year":"2018","unstructured":"Karst SG, Lammer J, Mitsch C et al (2018) Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Graefes Arch Clin Exp Ophthalmol 256:49\u201358. \n                    https:\/\/doi.org\/10.1007\/s00417-017-3828-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3952_CR4","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A et al (2012) Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119:2125\u20132132. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2012.04.030","journal-title":"Ophthalmology"},{"key":"3952_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3928\/23258160-20160901-06","volume":"47","author":"CP Shah","year":"2016","unstructured":"Shah CP, Heier JS (2016) Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and\/or bevacizumab may further improve macular thickness. Ophthalmic Surg Lasers Imaging Retin 47:836\u2013839. \n                    https:\/\/doi.org\/10.3928\/23258160-20160901-06","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"3952_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajo.2015.12.030","volume":"164","author":"E Rahimy","year":"2016","unstructured":"Rahimy E, Shahlaee A, Khan MA et al (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 164:118\u201327.e2. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2015.12.030","journal-title":"Am J Ophthalmol"},{"key":"3952_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/8035013","volume":"2017","author":"A Herbaut","year":"2017","unstructured":"Herbaut A, Fajnkuchen F, Qu-Knafo L et al (2017) Switching to aflibercept in diabetic macular edema not responding to ranibizumab and\/or intravitreal dexamethasone implant. J Ophthalmol 2017:1\u20138. \n                    https:\/\/doi.org\/10.1155\/2017\/8035013","journal-title":"J Ophthalmol"},{"key":"3952_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00417-017-3624-y","volume":"255","author":"B Bahrami","year":"2017","unstructured":"Bahrami B, Hong T, Zhu M et al (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255:1133\u20131140. \n                    https:\/\/doi.org\/10.1007\/s00417-017-3624-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-018-3952-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-3952-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-3952-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,10]],"date-time":"2019-03-10T01:01:39Z","timestamp":1552179699000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-018-3952-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,10]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["3952"],"URL":"https:\/\/doi.org\/10.1007\/s00417-018-3952-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,10]]},"assertion":[{"value":"26 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Manuel S. Falc\u00e3o has participated in advisory boards for Bayer and has received travel grants from Novartis, Alimera, and Allergan. The other authors declare no conflicts of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}